Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Aytu BioPharma Plans To Divest / Discontinue Non Core Assets

  • Aytu BioPharma Inc (NASDAQ:AYTUwill divest or discontinue non-core, unprofitable products, including Cefaclor, Flexichamber, Tuzistra XR, generic Tussionex, and Zolpimist. 
  • Aytu expects to improve gross margins for its ADHD product franchise by transferring manufacturing to a well-established, global commercial manufacturing organization, a transition expected to occur in mid-2023.
  • Aytu is commercializing two novel Attention Deficit Hyperactivity Disorder (ADHD) products, Adzenys XR-ODT and Cotempla XR-ODT, and pediatric products Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER.
  • Aytu has grown its ADHD prescriptions by 11% Y/Y YTD and its pediatric prescriptions by 18%.
  • Q3 sales increased 79% Y/Y to $24.2M, the highest revenue in company history.
  • Cash and cash equivalents totaled $27.6 million as of March 31.
  • The company reported a Q3 loss of $(53.1) compared to $(25.5) million a year ago, impacted by an impairment charge of $45.2 million.
  • Price Action: Monday, AYTU shares closed 5.85% lower at $0.49 on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.